Thymosin Beta-4 vs Ularitide
The body's natural healing peptide that accelerates tissue repair and reduces inflammation
A synthetic natriuretic peptide designed to help your heart pump better and remove excess fluid when you need it most.
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Quick comparison
Dose range
Thymosin Beta-4
2–5 mg
Ularitide
15–15 ng/kg/min
Frequency
Thymosin Beta-4
Twice weekly
Ularitide
Once daily
Administration
Thymosin Beta-4
Subcutaneous injection
Ularitide
Intravenous infusion
Cycle length
Thymosin Beta-4
8-12 weeks
Ularitide
Ongoing/indefinite
Onset speed
Thymosin Beta-4
Moderate (1-2 weeks)
Ularitide
Moderate (1-2 weeks)
Evidence level
Thymosin Beta-4
Moderate human trials (Phase 1-2)
Ularitide
Strong human trials (Phase 3 or FDA approved)
Benefit ratings
Wound Healing
Inflammation Reduction
Tissue Regeneration
Cardiovascular Support
Fluid & Electrolyte Balance
Kidney Protection
Compound specifications
Thymosin Beta-4
Molecular formula
C212H350N56O78S
Molecular weight
4963
Half-life
Dose-dependent (increases with higher doses)
Bioavailability
100% (subcutaneous and intravenous)
CAS number
77591-33-4
Ularitide
Molecular formula
C145H234N52O44S3
Molecular weight
3505.9
Half-life
6-7 minutes (in circulation)
Bioavailability
100% (intravenous administration)
CAS number
Not publicly assigned (proprietary compound)
Dosing compared
Thymosin Beta-4
Subcutaneous injection
2-5 mg (community injectable practice for 'TB-500')
Once or twice weekly · 4-6 week loading phase, then weekly maintenance
Documented community/research-practice injectable dosing for tissue repair; thymosin beta-4 has ~100% bioavailability by the subcutaneous route [1]. Not an FDA-approved use.
Topical ophthalmic (eye drops)
0.1% (1 mg/mL) RGN-259 solution, 1 drop
Several times daily (e.g. up to 5x/day) · 4 weeks
0.1% RGN-259 ophthalmic solution used in phase III neurotrophic keratopathy and dry-eye trials, applied as eye drops several times daily for ~4 weeks [5].
Intravenous injection
450-1200 mg
IV push daily for the first 3 days, then weekly · Total of 7 doses over ~5 weeks
Doses studied in the RGN-352 acute myocardial infarction clinical program, given IV after PCI [6].
Ularitide
Intravenous infusion
15 ng/kg/min
Continuous infusion · 48 hours
Dose and duration used in the TRUE-AHF trial (2157 patients) for acute heart failure; infusion reduced or stopped for systolic BP <100 mmHg [6]. Investigational only — not an approved drug.
Best suited for
Thymosin Beta-4
Post-Surgery Recovery
Accelerates healing of surgical wounds and reduces post-operative inflammation and scarring
Chronic Wound Management
Helps pressure ulcers, venous stasis ulcers, and other slow-healing wounds progress faster
Tissue Regeneration
Supports repair of damaged tissues from injury, burns, or degenerative conditions
Ularitide
Managing acute heart failure symptoms and fluid overload
Ularitide is particularly well-suited for individuals focused on managing acute heart failure symptoms and fluid overload. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1][7].
Improving oxygen delivery when your heart can't pump efficiently
Ularitide is particularly well-suited for individuals focused on improving oxygen delivery when your heart can't pump efficiently. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [7].
Protecting kidney function in critical heart patients
Ularitide is particularly well-suited for individuals focused on protecting kidney function in critical heart patients. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [8].
Side effects
Thymosin Beta-4
Common
- Injection site redness
- Injection site swelling
Uncommon
- Temporary mild headache
- Mild bruising at injection site
- Transient fatigue
Serious
- Allergic reaction
Ularitide
Common
- Dizziness or lightheadedness
- Low blood pressure (hypotension)
- Headache
- Nausea
Uncommon
- Elevated potassium levels
- Worsening kidney function (transient)
- Allergic reactions at injection site
- Chest discomfort
- Irregular heartbeat (arrhythmia)
Serious
- Severe hypotension requiring intervention
- Worsening heart function in some patients
- Acute kidney injury (rare)
- Anaphylactic shock (very rare)
Safety & evidence
Thymosin Beta-4
Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Thymosin Beta-4 is a naturally occurring peptide found in all cells and body fluids in the human body. Clinical trials have demonstrated excellent safety even at very high doses. IV studies showed doses up to 1260 mg were well tolerated with no serious adverse events.
Contraindications
- Active systemic infections
- Severe immunosuppression
- Hypersensitivity to thymosin or any component
- Pregnancy (insufficient safety data)
Ularitide
Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
Not FDA approved
Safety overview
Ularitide is a recombinant B-type natriuretic peptide approved in Europe for acute heart failure with safety data from Phase 3 trials showing favorable tolerability compared to placebo and nesiritide. Hypotension is the primary dose-limiting adverse effect, requiring baseline blood pressure assessment and careful hemodynamic monitoring during IV infusion. [6][7][10] Natriuretic peptide class risks include worsening renal function in some patients [6] and hypokalemia (electrolyte abnormalities from enhanced diuresis), necessitating electrolyte monitoring during acute phase therapy.
Contraindications
- Hypotension (dangerously low blood pressure)
- Cardiogenic shock without proper monitoring
- Severe renal dysfunction in some cases
- Allergy to synthetic peptides
Which is right for you?
Choose Thymosin Beta-4 if...
- Recovering from injuries or surgery
- Improving wound healing speed
- Reducing inflammation
- Minimizing scar formation
Choose Ularitide if...
- Managing acute heart failure symptoms and fluid overload
- Improving oxygen delivery when your heart can't pump efficiently
- Protecting kidney function in critical heart patients